Atopic dermatitis imposes a significant patient burden, which includes itching, sleep disruption, and a reduction in health-related quality of life. Changes in patient-reported outcomes of disease-specific signs/symptoms and health-related quality of life were assessed in adult and adolescent patients with moderate-to-severe atopic dermatitis treated with once-daily oral abrocitinib 200-mg or 100-mg monotherapy. The researchers examined data from one phase IIb (NCT02780167) and two-phase III monotherapy studies in adults and adolescents with moderate-to-severe atopic dermatitis. Global severity, itch, and multi-item measures that assess various signs and symptoms of atopic dermatitis were among the patient-reported outcome evaluations. Additional patient-reported outcome evaluations looked at sadness, anxiety, tiredness, disease-specific and overall health-related quality of life, as well as job and general productivity among employed patients. 

In all, 942 patients were enrolled in this study. Improvements in all patient-reported outcomes were observed from the first post-baseline assessment to week 12, including a Patient Global Assessment (PtGA) score of 0/1, a 4-point improvement in the Night-Time Itch Scale, a change from baseline in the Patient-Oriented Eczema Measure (POEM) score, a 1-point improvement in the Pruritus and Symptoms Assessment for Atopic Dermatitis, Hospital Anxiety and Depression. 

Reference: https://link.springer.com/article/10.1007/s40257-021-00604-9

Author